Alembic Pharma JV gets EIR from USFDA for Karakhadi facility

The EIR is for the inspection carried out by USFDA at Alembic Pharma's joint venture, Aleor Dermaceuticals' at Karakhadi, Gujarat, India during the period from February 4, 2019 to February 8, 2019.

Mumbai: Aleor Dermaceuticals Ltd (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd (Alembic) and Orbicular Pharmaceutical Technologies Pvt Ltd (Orbicular), has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA).

Also Read: Alembic Pharma gets USFDA approval for Olopatadine Hydrochloride Ophthalmic Solution

The EIR is for the inspection carried out by USFDA at Aleor's Formulation Facility at Karakhadi, Gujarat, India during the period from February 4, 2019 to February 8, 2019, Alembic Pharma said in a filing with BSE.

Alembic Pharmaceuticals Limited, vertically integrated research and development the pharmaceutical company has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

Also Read: Alembic Pharma gets USFDA nod toTeriflunomide tablets, Tobramycin ophthalmic solution